|
“The event as usual was highly interesting and useful from my perspective of mingling with the industry delegates and learning about their different issues” Kevin Bacon, Founder, Chief Scientific Officer & Head, Research & Development, Actimis
“I very much enjoyed the conference last May and would be happy to participate in the Advisory Board for the next meeting”
Chris Compton, Executive Director Clinical Research & Development, Pfizer
Global asthma/COPD sales should grow to $23 billion by 2014, with inhaled corticosteroid/long-acting bronchodilator combinations set to be the leading class by value in 2014, followed by leukotriene antagonists, and anticholinergics.
Through a series of case studies and novel research overviews from the leading pharmaceutical companies, SMi’s 4th annual conference on Asthma & COPD will explore the new drugs in the R&D pipeline. The conference will examine patient compliance and adherence in asthma and COPD, inspect the emerging novel treatments and drug therapies, highlight the development and use of biomarkers through to the use of clinical endpoints in Asthma & COPD, as well as cover up-to-date regulatory developments from the FDA and MHRA.
This is your exclusive opportunity to benchmark your company by hearing from the industry leaders already at the forefront of this dynamic market.
OUR EXPERT PANEL OF SPEAKERS INCLUDES:
- Dr Chris Compton, Executive Director Clinical R&D, Pfizer
- Dr Keith Allan, Head of Global Advocacy, Novartis
Dr Alex Bell, Product Development Manager, 3M Healthcare - Dr Noel Snell, Global Medical Science Director, AstraZeneca
- Dr Heribert Staudinger, Vice President, Clinical Development, Schering Plough
- Dr Ewan Walters, Medical Director, Teva
Professor Tim Higenbottam, Global Clinical Expert, Senior Principle Scientist, AstraZeneca Dr Dzelal Serdarevic, Director, A&R Therapeutic Area, Clinical R&D, Pfizer Dr Shahin Sanjar, Senior Director Respiratory Sciences, Altana Pharma US Dr Mark Parry-Billings, Chief Development Officer, Topigen Pharmaceuticals Dr Phillip Monk, Head of Development, Synairgen Dr Malinda Longphre, Clinical Director, Aerovance Dr Matthew Catley, Senior Scientist, UCB Dr Steve Pascoe, Global Head Respiratory/ Dermatology Profiling Exploratory Clinical Development, Novartis Dr Aleck Harrison, Consultant Clinical Scientist, Vitalograph Dr Hans-Juergen Smith, Product Manager Pneumonology, Viasys Professor Derek Hill, CEO, Ixico
Chaired by: - Professor Peter Barnes, Head of Respiratory Medicine, Imperial College London
- Dr Mark Parry-Billings, Chief Development Officer, Topigen Pharmaceuticals
7 KEY BENEFITS OF ATTENDING
- GAIN a valuable insight into the current pipeline developments in the respiratory arena
- IDENTIFY new drug developments and concepts
- REVIEW the clinical endpoints that are currently being accepted
- EXAMINE novel approaches to improving patient adherence and compliance
- HEAR case studies from the world leaders in respiratory drug discovery
- QUANTIFY the future size and scope of the asthma/COPD market and predict the future performance of key compounds
- UNDERSTAND the latest up-to-date regulatory developments including the recent FDA draft guideline on COPD
WHO SHOULD ATTEND ASTHMA AND COPD?
You should attend this conference if you are an Executive, Director or scientist working in the pharmaceutical or biotech industries within: - Respiratory Science
- Research & Development
- Inflammation
- Clinical & Regulatory Affairs
- Drug Discovery
- Respiratory Illness
- Inhalation Drug Delivery
- Project Management
- Preclinical Development
- Portfolio Management
- Marketing
PREVIOUS DELEGATES HAVE BEEN FROM THE FOLLOWING COMPANIES: - Pfizer
- GlaxoSmithKline
- Merck
- Novartis
- AstraZeneca
- Wyeth
- Sanofi-Aventis
- Astellas
- Roche
- UCB
- Teva
- Eli Lilly
- Boehringer-Ingelheim
- Abbott
- Amgen
- Schering Plough
- MHRA
- Taligen Therapeutics, Inc.
- Wood Mackenzie
- Merck Sharp & Dohme
- Thomson Scientific
- MD Biosciences
- Laboratorios Almirall
- Biolipox
- Biota
- 3M Healthcare
- Ono Pharma UK Ltd
- Dyax Corporation
- Nspire Health
- Elbion GmbH
- NeuroSearch A/S
- Activaero
- CRS Group
- Mundipharma
- Merck Serono
- CESP
|
Events Home Page
